Markets:

Overview

News

Currencies

International

Treasuries

BioCryst Pharmaceuticals, Inc. - Common Stock (NQ:BCRX)

7.990 -0.060 (-0.75%)

Delayed Quote Updated: 3:23 PM EDT, Oct 15, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about BioCryst Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >

BioCryst Pharmaceuticals (BCRX) Q3 2021 Earnings Call Transcript ↗

November 03, 2021

BCRX earnings call for the period ending September 30, 2021.

Via The Motley Fool

Topics Earnings

Here's Why BioCryst Pharmaceuticals Stock Is Losing Ground Today ↗

November 03, 2021

The biotech's third quarter was a good one, once you look past the top-line numbers.

Via The Motley Fool

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

November 03, 2021

Gainers iRhythm Technologies (NASDAQ:IRTC) stock moved upwards by 52.78% to $117.34 during Wednesday's regular session. iRhythm Technologies's stock is trading at...

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

November 03, 2021

Gainers Glaukos (NYSE:GKOS) stock increased by 25.55% to $56.58 during Wednesday's pre-market session. The market value of their outstanding shares is at $2.6 billion...

Via Benzinga

Analyzing BioCryst Pharmaceuticals's Unusual Options Activity ↗

August 11, 2021

BioCryst Pharmaceuticals (NASDAQ:BCRX) shares experienced...

Via Benzinga

Analyzing BioCryst Pharmaceuticals's Unusual Options Activity ↗

July 30, 2021

Shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) saw some...

Via Benzinga

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

October 20, 2021

Gainers Tenet Healthcare (NYSE:THC) stock r...

Via Benzinga

2 Super-Charged Growth Stocks to Buy Now ↗

October 13, 2021

These two small drugmakers are poised for a long-winded growth spurt.

Via The Motley Fool

NICE Recommends BioCryst's Hereditary Angioedema Med ↗

September 16, 2021

The U.K.'s National Institute for Health and Care Excellence (NICE) has recommended BioCryst Pharmaceuticals Inc's (NASDAQ: BCRX) Orladeyo (berotralstat)...

Via Benzinga

US Government Exercises Option To Buy Additional Doses Of BioCryst's Flu Med ↗

September 01, 2021

The U.S. Department of Health and Human Services (HHS) has exercised its option to purchase an additional 10,000 doses of BioCryst Pharmaceuticals Inc's (...

Via Benzinga

The Daily Biotech Pulse: Early Approval For Ascendis' Pediatric Growth Hormone Deficiency Treatment, Redhill Biopharma Spikes On Positive COVID-19 Drug Data, RenovoRx IPO ↗

August 26, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 25) Abbvie Inc. (NYSE: ABBV)...

Via Benzinga

Analyzing BioCryst Pharmaceuticals's Unusual Options Activity ↗

August 16, 2021

BioCryst Pharmaceuticals (NASDAQ:BCRX) shares experienced unusual options activity on Monday. The stock price moved down to $15.44 following the option alert. Sentiment: BULLISH...

Via Benzinga

BioCryst Stock Jumps After Pulling Out $200M Equity Raise ↗

August 11, 2021

BioCryst Pharmaceuticals Inc (NASDAQ: BCRX) has withdrawn its proposed public offering of $200 million of its stock and pre-funded warrants. The Company says...

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

August 11, 2021

Gainers CohBar (NASDAQ:CWBR) stock moved upwards by 68.21% to $2.17 during Wednesday's pre-market session. The company's market cap stands at $134.0 million. The...

Via Benzinga

22 Stocks Moving in Wednesday's Pre-Market Session ↗

August 11, 2021

Gainers CohBar, Inc. (NASDAQ: CWBR) shares rose 78.3% to $2.30 in pre-market trading after the company reported results from the Phase 1a/1b study of CB4211 under development for...

Via Benzinga

The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering ↗

August 11, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 10) Alnylam Pharmaceuticals,...

Via Benzinga

85 Biggest Movers From Yesterday ↗

August 11, 2021

Gainers Fulcrum Therapeutics, Inc. (NASDAQ: FULC) jumped 125.3% to close at $18.77 on Tuesday after the company announced positive interim results from the Phase 1 trial with FTX...

Via Benzinga

54 Stocks Moving In Tuesday's Mid-Day Session ↗

August 10, 2021

Gainers Fulcrum Therapeutics, Inc. (NASDAQ: FULC) climbed 79.3% to $14.93 after the company announced positive interim results from the Phase 1 trial with FTX-6058 in healthy...

Via Benzinga

28 Stocks Moving in Tuesday's Pre-Market Session ↗

August 10, 2021

Gainers Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) shares rose 38.6% to $66.88 in pre-market trading after the company reported better-than-expected Q2 earnings and also...

Via Benzinga

The Daily Biotech Pulse: Dicerna Slips On Data, Novavax Tightlipped On US Vaccine Approval, Adagio IPO ↗

August 06, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 5) Alkermes plc (NASDAQ: ALKS)...

Via Benzinga

BioCryst Pharmaceuticals (BCRX) Q2 2021 Earnings Call Transcript ↗

August 06, 2021

BCRX earnings call for the period ending June 30, 2021.

Via The Motley Fool

Topics Earnings

Why BioCryst Pharmaceuticals Rose 8% on Thursday ↗

August 05, 2021

The company's first commercial drug launch keeps exceeding expectations.

Via The Motley Fool

Topics Earnings

BioCryst Pharma Stock Heads Higher Thursday: Here's Why ↗

August 05, 2021

BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) shares were trading higher Thursday after the company reported second-quarter financial results. The company reported revenue of...

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

August 05, 2021

Gainers Ensysce Biosciences (NASDAQ:ENSC) shares rose 42.78% to $5.84 during Thursday's pre-market session. The company's market cap stands at $141.7 million....

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For August 3, 2021 ↗

August 03, 2021

Upgrades For SolarEdge Technologies Inc (NASDAQ:

Via Benzinga

Analyzing BioCryst Pharmaceuticals's Unusual Options Activity ↗

July 29, 2021

BioCryst Pharmaceuticals (NASDAQ:BCRX) shares experienced unusual options activity on Thursday. The stock price moved up to $16.93 following the option alert. Sentiment: BULLISH...

Via Benzinga

Unusual Options Activity Insight: BioCryst Pharmaceuticals ↗

July 23, 2021

On Friday, shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) saw unusual options activity. After the option alert, the stock price moved up to $17.1. Sentiment: BULLISH Option...

Via Benzinga

BioCryst Outlines Pivotal Trial Designs For BCX9930 In Rare Blood Disorder ↗

July 15, 2021

BioCryst Pharmaceuticals Inc (NASDAQ: BCRX) has announced the designs for REDEEM-1 and REDEEM-2, two upcoming pivotal trials for its oral Factor D inhibitor,...

Via Benzinga

BioCryst Shares 96-Week Orladeyo Data Highlighting 80% Reduction In HAE Attacks ↗

July 12, 2021

BioCryst Pharmaceuticals Inc (NASDAQ: BCRX) has announced 96-week data from the Phase 3 APeX-2 trial for Orladeyo (berotralstat), showing a sustained reduction in...

Via Benzinga

18 Key Biopharma Catalysts To Keep An Eye On In Q3 ↗

July 10, 2021

Biopharma stocks underperformed in the first half of 2021, and several of these stocks could be in for a rebound in the coming months. Ne...

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.